AN2 Therapeutics financials
$5.09+1.60%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY17 Dec 31 | FY16 Dec 31 | FY15 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $90.04B | $84.86B | $79.16B |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $17.80B | $18.03B | $18.04B |
| Gross margin | — | — | — | — | 19.8% | 21.2% | 22.8% |
| Operating income | -$38.1M | -$56.8M | -$69.6M | -$42.3M | $4.70B | $5.28B | $5.28B |
| Net income | -$35.2M | -$51.3M | -$64.7M | -$42.8M | $3.84B | $2.47B | $2.56B |
| Net margin | — | — | — | — | 4.3% | 2.9% | 3.2% |
| Diluted EPS | $-1.16 | $-1.72 | $-2.74 | $-2.79 | $14.35 | $9.21 | $9.38 |
| EBITDA | -$38.1M | -$54.6M | -$69.6M | -$42.3M | $5.88B | $6.19B | $6.18B |
| Operating cash flow | -$29.8M | -$49.3M | -$53.3M | -$33.5M | $4.18B | $3.27B | $4.21B |
| Free cash flow | -$29.8M | -$49.3M | -$53.3M | -$33.5M | $3.39B | $2.69B | $3.57B |
| Diluted shares | 30.2M | 29.8M | 23.6M | 15.3M | 267.8M | 268.1M | 272.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $19.9M | $21.4M | $15.6M | $27.2M | $3.61B | $4.08B |
| Short-term investments | $38.1M | $62.3M | $91.6M | $68.8M | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $19.93B | $15.73B |
| Total assets | $62.0M | $92.1M | $138.7M | $102.6M | $70.54B | $65.08B |
| Total liabilities | $8.9M | $10.2M | $14.0M | $7.2M | $44.04B | $39.98B |
| Shareholders' equity | $53.1M | $81.8M | $124.7M | $95.4M | $26.50B | $25.10B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology